Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
san francisco top stories
4
×
boston blog main
boston top stories
clinical trials
drugs
national top stories
biotech
boston
deals
fda
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
san francisco
wisconsin blog main
wisconsin top stories
accelerator
airbnb
akcea therapeutics
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
amazon web services (aws)
arrowhead pharmaceuticals
artificial intelligence (a.i.)
athelas
atomwise
barry greene
benchling
biotechnology
boehringer ingelheim
boston university
cancer
cannabidiol
coinbase
What
ago
4
×
companies
fda
medicine
rna
abandoning
admits
alnylam
approve
approved
awaits
baggage
battle
big
biological
biotechs
cannabis
classes
combinator
crossed
cuts
data
deal
decades
decision
derivative
development
dicerna
discovered
drug
dug
epilepsy
fingers
form
free
friday
gets
gw
gw’s
historic
Language
unset
Current search:
ago
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug